ERBB2 and neoplasm: This pathway has been most prominently studied with trastuzumab which showed that PIK3CA mutations resulted in decreased sensitivity to the ADC, and that adding a PI3K inhibitor to trastuzumab had enhanced anti-tumor activity in HER2-positive metastatic breast cancer (70, 71).